CLAIMS

1. Use of a CD96-inhibitory agent in the manufacture of a medicament for reducing or relieving immune inhibition in a mammal, said use including the step of at least partly inhibiting or reducing CD96 activity in one or more cells of the mammal to thereby relieve immune inhibition and/or enhance or restore immune surveillance in the mammal, wherein the step of at least partly inhibiting or reducing CD96 activity in the mammal includes a CD96-inhibitory agent to be administered to the mammal.

2. The use of Claim 1, wherein the step of at least partly inhibiting or reducing CD96 activity in the mammal does not include, or at least depend upon killing of CD96-expressing cells in the mammal.

3. The use of Claim 1, wherein the CD96-inhibitory agent binds or interacts with one or a plurality of external immunoglobulin-like domains of CD96.

4. The use of Claim 1, wherein the CD96-inhibitory agent binds or interacts with: one or a plurality of external immunoglobulin-like domains of CD96 selected from the group consisting of; domain 1; domain 2; domain 3; domain 1 and domain 2; domain 1 and domain 3: domain 2 and domain 3; and domain 1, domain 2 and domain 3.

5. The use of Claim 3 or Claim 4, wherein the CD96-inhibitory agent binds or interacts with one or a plurality of external immunoglobulin-like domains of human CD96 isoform 2 (SEQ ID NO:2).

6. The use of any one or Claims 1-5, wherein the CD96-inhibitory agent at least partly blocks or inhibits CD96 binding to CD 155 and/or intracellular signalling by CD96.

7. The use of Claim 6, wherein the CD96-inhibkory agent is an anti-CD96 antibody or antibody fragment.

8. The use of any preceding claim which includes one or more other therapeutic agents to be administered.

9. The use of Claim 8, wherein the one or more other therapeutic agents include a chemotherapeutic agent and one or more antibodies or antibody fragments that bind PDI and/or CTLA4.

10. The use of any preceding claim, which increases or enhances cytokine and/or chemokine expression and/or secretion by one or more cells in the mammal.

11. The use of Claim 10, wherein the cytokine and/or chemokines include MIP-1α, MIP-1β, RANTES, TNF-α and IFN-γ.

12. The use of Claim 11, wherein the cytokine is interferon γ (IFN-γ).

13. The use of Claim 10, Claim 11 or Claim 12, wherein the one or more cells are T cells, inclusive of $CD4^+$ and $CD8^+$ T cells, γδ T cells and NK T cells and natural killer (NK.) cells.

14. The use of any preceding claim, which treats or prevents cancer or cancer metastasis in the mammal.

15. The use of any preceding claim, which treats or prevents a viral infection in the mammal.

16. The use of any preceding claim, wherein the mammal is a human.

17. A method of screening, designing, engineering or otherwise producing a CD96-inhibitory agent, said method including the step of determining whether a candidate molecule is capable of at least partly inhibiting or reducing CD96 activity to thereby relieve immune inhibition and/or enhance or restore immune surveillance in a mammal.

18. The method of Claim 17 wherein the CD96-inhibitory agent binds or interacts with one or a plurality of external immunoglobulin-like domains of CD96.

19. The method of Claim 18, wherein the CD96-inhibitory agent binds or interacts with one or a plurality of external immunoglobulin-like domains of CD96 selected from the group consisting of; domain 1; domain 2; domain 3; domain 1 and domain 2; domain 1 and domain 3: domain 2 and domain 3; and domain 1, domain 2 and domain 3.

20. The method of Claim 18 or Claim 19 wherein the CD96-inhibitory agent binds or interacts with one or a plurality of external immunoglobulin-like domains of human CD96 isoform 2 (SEQ ID NO:2).

21. The method of any one of Claims 17-20, wherein the CD96-mhibitory agent is an antibody or antibody fragment.

22. The method of any one of Claims 17-21, wherein the CD96-inhibitory agent is an anti-cancer agent.

23. The method of any one of Claims 14-22, wherein the CD96-inhibitory agent is an anti-viral agent.

24. The method of any one of Claims 17-23, wherein the mammal is a human.

25. A CD96-inhibitory agent screened, designed, engineered or otherwise produced according to the method of any one of Claims 17-24.

26. The CD96-inhibitoty agent of Claim 25 for use according to any one of Claims 1-16.